ADGRD1 as a Potential Prognostic and Immunological Biomarker in Non‐Small‐Cell Lung Cancer
Open Access
- 22 November 2022
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5699892
Abstract
ADGRD1 (GPR133), an adhesion G protein‐coupled receptor (GPCR), has been linked to cancer. However, the prognostic value and regulatory function within non‐small‐cell lung cancer (NSCLC) is still unclear. This work adopted various bioinformatics methods, including publicly available databases as well as real‐time PCR (RT‐PCR), for detecting ADGRD1 expression level and investigating the correlation between ADGRD1 expression level and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), immune infiltrating cells, immune‐related genes, and targeted regulation mechanisms in NSCLC. According to the results, ADGRD1 expression decreased within NSCLC, which might be the factor predicting prognosis of NSCLC. Meanwhile, ADGRD1 showed significant correlation with TMB and MSI, respectively, as well as immune cell infiltrating levels in lung adenocarcinoma (LUAD), which were primarily linked to macrophage M1, mast cell resting, T cell CD4 memory activated, and T cell CD4 memory resting and were associated with mast cell activated and mast cell resting in lung squamous cell carcinoma (LUSC). The most promising upstream regulation pathways of ADGRD1 were likely miR‐142‐5p, miR‐93‐5p, and miR‐17‐5p, which were overexpressed and associated with poor prognosis in NSCLC. ADGRD1 and immune‐related genes correlated with ADGRD1 were shown to be enriched in “positive regulation of leukocyte activation,” “external side of plasma membrane,” “receptor ligand activity,” and “cytokine‐cytokine receptor interaction” pathways. ADGRD1 expression and regulation may be critical in determining NSCLC prognosis.Keywords
Funding Information
- National Natural Science Foundation of China (82273720)
This publication has 40 references indexed in Scilit:
- miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancerBMC Cancer, 2017
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersMolecular Cancer Therapeutics, 2017
- A comprehensive map of molecular drug targetsNature Reviews Drug Discovery, 2016
- Classification and characterization of microsatellite instability across 18 cancer typesNature Medicine, 2016
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancerNature Communications, 2014
- Cell Adhesion Receptor GPR133 Couples to Gs ProteinJournal of Biological Chemistry, 2011
- Microsatellite instability in colorectal cancer—the stable evidenceNature Reviews Clinical Oncology, 2010
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008